Campbell Elizabeth J, Dachs Gabi U
Mackenzie Cancer Research Group, Department of Pathology, University of Otago , Christchurch , New Zealand.
Front Oncol. 2014 Oct 14;4:282. doi: 10.3389/fonc.2014.00282. eCollection 2014.
The role of vitamin C (ascorbate) in cancer prevention, tumor growth, and treatment is of intense public interest. Clinical trial data have been sparse, contradictory, and highly controversial, and robust pre-clinical data are required for progress. This paper reviews pre-clinical models and their limitations with respect to ascorbate research. Most studies have utilized animals able to synthesize ascorbate and thus are not ideal models of the human condition. More recently, genetically modified mouse models have become available; yet, all studies compared healthy and scorbutic mice. The majority of investigations to date concluded that increased ascorbate led to decreased tumor growth, but data on mechanisms and doses are inconclusive. Clinically relevant animal studies are still required to convince a generally sceptical medical audience of the potential worth of ascorbate as an adjunct to therapy.
维生素C(抗坏血酸)在癌症预防、肿瘤生长和治疗中的作用备受公众关注。临床试验数据稀少、相互矛盾且极具争议性,因此需要强有力的临床前数据来推动研究进展。本文综述了临床前模型及其在抗坏血酸研究方面的局限性。大多数研究使用的是能够合成抗坏血酸的动物,因此并非人类情况的理想模型。最近,基因改造小鼠模型已可用;然而,所有研究都是将健康小鼠和患坏血病的小鼠进行比较。迄今为止,大多数研究得出结论,抗坏血酸增加会导致肿瘤生长减缓,但关于作用机制和剂量的数据尚无定论。仍需要开展具有临床相关性的动物研究,以使普遍持怀疑态度的医学界相信抗坏血酸作为治疗辅助手段的潜在价值。